Our research projects aimed at a better understanding of lung cancer and MPM development and drug resistance are funded by the Swiss National Science Foundation (SNSF), the Swiss Cancer Research foundation and the Swiss Cancer League as well as the Cancer League of the Canton of Bern. Over the past decade, we have discovered several key events in the oncogenic process of lung cancer and MPM pathogenesis and progression, with several original scientific findings of translational importance being investigated under clinical conditions.
Deciphering therapeutic resistance in KRAS-mutant lung cancer.
Uncovering new therapeutic rationales through integrative molecular characterization of malignant pleural mesothelioma (MPM).
Towards a precision medicine approach for FGFR1-amplified lung cancer.
Ferroptosis as an avenue to target lung cancer and MPM.